NCT04257175View on ClinicalTrials.gov

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CAR-T CD19

The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).

Trial Locations (1)

57261

RECRUITING

Chaim Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV